Twelve-Year Real-World Evaluation of a Regulated Guideline-Based Warfarin Dosing and Care Automation System
- 1Forsante Ltd.
Abstract
BackgroundWarfarin therapy requires repetitive dose adjustments based on INR (International Normalised Ratio) monitoring. We evaluated the long-term real-world performance of Forsante Warfarin Advisor (WA), a CE-marked class IIb guideline-based decision support and care automation medical device used in anticoagulation management.
MethodsRetrospective real-world data from routine clinical use between 2014 and 2026 were analysed. Treatment quality was assessed using Time in Therapeutic Range (TTR). Recommendation performance was evaluated by comparing achievement of target INR after clinician acceptance or modification of Warfarin Advisor recommendations.
ResultsAmong 1348 patients in March 2026 median TTR was 83%, compared with 70% in March 2016. Dosages congruent with Warfarin Advisor recommendations were strongly associated with achieving target INR at follow-up in INR target ranges of 2.0-3.0 and 2.5-3.5. Treatment quality remained consistently high across years of deployment. No serious device-attributable safety incidents, regulatory incident reports, or CAPA cases were identified during 12 calendar years and 82,709 patient years of routine use.
ConclusionsThe findings provide real-world long-term evidence that a guideline-based warfarin dosing and care automation system can support sustained high-quality anticoagulation control in routine clinical practice. They support the feasibility of deploying workflow-integrated execution of selected guideline-driven clinical processes, while the causal effects on clinical outcomes require prospective confirmation.
Related
- Automation of literature screening for meta-analyses in the field of psychology: an evaluation of two text-mining approaches.
- Transcriptomic Profiles Carry Most of the Multi-Omics Signal for Drug Sensitivity Prediction in Cancer Cell Lines: A Cross-Lineage and Independent-Screen Evaluation of Twelve Anticancer Agents
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
- Guideline adherence and expert-rated potential safety concerns in AI-generated dietary advice for patients with cirrhosis: a comparative evaluation of large language models.
- Development and evaluation of Retrieval-Augmented Generation (RAG) and GraphRAG for guideline-based clinical decision support in chronic kidney disease
BibTeX
@misc{tiihonen2026twelveyear,
title = {{Twelve-Year Real-World Evaluation of a Regulated Guideline-Based Warfarin Dosing and Care Automation System}},
author = {M. Tiihonen},
howpublished = {medRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.10.26360059},
url = {https://www.medrxiv.org/content/10.64898/2026.08.10.26360059v2},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Twelve-Year Real-World Evaluation of a Regulated Guideline-Based Warfarin Dosing and Care Automation System
AU - M. Tiihonen
PY - 2026
DA - 2026/08/10
PB - medRxiv
DO - 10.64898/2026.08.10.26360059
UR - https://www.medrxiv.org/content/10.64898/2026.08.10.26360059v2
AB - BackgroundWarfarin therapy requires repetitive dose adjustments based on INR (International Normalised Ratio) monitoring. We evaluated the long-term real-world performance of Forsante Warfarin Advisor (WA), a CE-marked class IIb guideline-based decision support and care automation medical device used in anticoagulation management. MethodsRetrospective real-world data from routine clinical use between 2014 and 2026 were analysed. Treatment quality was assessed using Time in Therapeutic Range (TTR). Recommendation performance was evaluated by comparing achievement of target INR after clinician acceptance or modification of Warfarin Advisor recommendations. ResultsAmong 1348 patients in March 2026 median TTR was 83%, compared with 70% in March 2016. Dosages congruent with Warfarin Advisor recommendations were strongly associated with achieving target INR at follow-up in INR target ranges of 2.0-3.0 and 2.5-3.5. Treatment quality remained consistently high across years of deployment. No serious device-attributable safety incidents, regulatory incident reports, or CAPA cases were identified during 12 calendar years and 82,709 patient years of routine use. ConclusionsThe findings provide real-world long-term evidence that a guideline-based warfarin dosing and care automation system can support sustained high-quality anticoagulation control in routine clinical practice. They support the feasibility of deploying workflow-integrated execution of selected guideline-driven clinical processes, while the causal effects on clinical outcomes require prospective confirmation.
ER -